ArticleFundamental research2025
Modeling the modulation of beta oscillations in the basal ganglia by dual-target optogenetic stimulation.
Article in Fundamental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SpikeAEC: a neuromodulation-based spiking controller for explore-exploit balancing in mobile robots.Frontiers in neurorobotics · 2026Article
- Multimodal technologies for neural modulation and sensing.Fundamental research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optogenetic techniques provide precise control over the activity of specific neurons within the nucleus, offering more accurate regulatory effects compared to deep brain stimulation. The heterogeneity of the globus pallidus externa (GPe) has garnered wide attention, wherein significant differences in pathological changes emphasize its potential as a stimulation target with distinct mechanisms. A basal ganglia-thalamus (BG-Th) network model incorporating heterogeneous GPe is developed to explore potential optogenetic stimulation targets for treating Parkinson's disease (PD). Initially, the modulation mechanisms of single-target optogenetic stimulation on the abnormal rhythmic oscillations of BG nuclei are examined. Excitation of D1 medium spine neuron (MSN), calcium-binding protein parvalbumin (PV) GPe, and inhibition of globus pallidus interna (GPi) can effectively suppress synchronous bursting activity in GPi, while excitation of GPi promotes high-frequency discharge to disrupt beta oscillations. Furthermore, dual-target optogenetic stimulation strategies are devised to reduce energy consumption. Results show that targets with similar mechanisms exhibit additive effects, whereas targets with opposing mechanisms lead to cancellation. The underlying effective mechanisms of dual-target strategies are: enhancing the inhibitory input to GPi thus inhibiting the activity of GPi, or disrupting beta oscillations by restoring high-frequency discharges in GPi. The strategy composed of exciting D1 MSN and inhibiting GPi requires the minimum total light intensity among single-target and dual-target strategies in our simulation. Furthermore, simultaneously enhancing PV GPe and inhibiting D2 MSN achieves the greatest reduction in total energy consumption (40.8% reduction), compared to only enhancing PV GPe. The findings unveil effective circuit mechanisms of optogenetic stimulation and provide novel insights for designing precise regulatory strategies for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.